Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From CellScape Corp.

The A-List: The Trend-Shaping Series A Financings Of 2014

In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.

BioPharmaceutical Medical Device

Noninvasive Prenatal Screening: Battleground In Diagnostics Innovation

Four companies have brought noninvasive prenatal testing to the market within the past two years. Its dramatic, rapid uptake has triggered a backlash among many geneticists, who fear the consequences of a poorly understood – and overhyped – technology.

Medical Device BioPharmaceutical

Molecular Diagnostics Ushers In New Era Of Prenatal Testing

The recent launch of several noninvasive gene-based tests for Down syndrome and other fetal chromosomal abnormalities is poised to upend current prenatal screening practices and potentially usher in a new, multibillion-dollar market opportunity in the process. These new tests employ next-generation gene sequencing, along with advanced, risk-based computer algorithms, to detect and characterize fetal genetic abnormalities using the DNA present in a maternal blood sample. And because they are actually able to “interrogate” the DNA, they represent a huge technological advance over the current standard-of-care for prenatal screening.

Medical Device Legal Issues

Device/Diagnostics Quarterly Deal Statistics, Q1 2012

Medical device companies raised $1.1 billion, a 40% increase over Q4 2011’s $800 million. Two billion-dollar deals in the resuscitation market boosted device acquisition activity to $4.2 billion. Twenty diagnostics financings brought in a collective $302 million, soaring above the previous quarter’s $269 million. There were seven diagnostics M&A deals completed, totaling $589 million – down yet again.

Medical Device Deals
See All

Company Information

  • Industry
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
UsernamePublicRestriction

Register